Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Athens :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Birmingham : University of Alabama

A Study of Modified Stem Cells in Stable Ischemic Stroke

Birmingham : The University of Alabama at Birmingham

Aspirin in Reducing Events in the Elderly

Birmingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Birmingham :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Birmingham : 1160.129.32261 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Birmingham : University of Alabama, Birmingham

Right to Left Cardiac Shunt Detection

Birmingham : University of Alabama

Safety of Intravenous Thrombolysis for Wake-up Stroke

Columbiana :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fairhope : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gulf Shores : 1160.129.32023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hoover :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Huntsville : Huntsville Hospital / Heart Center Research LLC

AMPLATZER Cardiac Plug Clinical Trial

Huntsville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Huntsville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Mobile : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mobile :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Mobile :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Mobile : University of South Alabama

Insulin Resistance Intervention After Stroke Trial

Ozark :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pell City : 1160.129.32172 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Scottsboro : 1160.129.32054 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tuscaloosa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Tuscaloosa : 1160.129.32174 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Anchorage : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Anchorage : 1160.129.32335 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Jonesboro : 1160.129.32150 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chandler :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Chandler : 1160.129.32254 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Gilbert : Mercy Gilbert and Chandler Medical Center

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

Gilbert :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Glendale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Glendale :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Glendale : 1160.129.32284 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Goodyear :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Hot Springs : 1160.129.32156 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Havasu City : 1160.129.32151 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Mesa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Phoenix : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Phoenix :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Phoenix : 1160.129.32159 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Phoenix : 1160.129.32250 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Phoenix : Heart and Vascular Center of Arizona

Right to Left Cardiac Shunt Detection

Phoenix : Carl T. Hayden Medical Research Foundation

SmartRisk Stroke Prediction by MRI of Carotid Disease

Sierra Vista :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Tempe :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Tucson :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Tucson :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Tucson : University of Arizona

Insulin Resistance Intervention After Stroke Trial

Fort Smith :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fort Smith : 1160.129.32266 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hot Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hot Springs : 1160.129.32140 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Jonesboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Little Rock : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Little Rock :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Little Rock : 1160.129.32014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Little Rock : 1160.129.32346 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Little Rock : 1160.129.32009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Colton : SHANTI Clinical Trials

Stroke

Aliso Viejo : Avanir Pharmaceuticals

PRISM Registry: Pseudobulbar Affect Registry Series

Anaheim :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Beverly Hills :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Buena Park :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Carlsbad :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Carmichael : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Carmichael :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Citrus Heights :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Costa Mesa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Covina :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Downey :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Downey : Merz Investigational Site #001184

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

El Cajon :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Encinitas : 1160.129.32035 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Escondido : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fair Oaks :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fountain Valley : 1160.129.32126 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fresno : 1160.129.32019 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fresno : UCSF-Fresno

Insulin Resistance Intervention After Stroke Trial

Fullerton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Garden Grove : Merz Investigational Site #001208

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Glendale : California Clinical Trials

Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects

Greenbrae :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Hawaiian Gardens : 1160.129.32305 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : 1160.129.32230 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Huntington Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Huntington Park :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Irvine :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

La Jolla :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

La Jolla : 1160.129.32225 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

La Jolla : Scripps Clinic

Insulin Resistance Intervention After Stroke Trial

La Mesa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

La Mesa : 1160.129.32216 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Laguna Hills : Alliance Research Centers

Right to Left Cardiac Shunt Detection

Lakewood :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lancaster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lancaster :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lincoln :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Loma Linda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lomita :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Long Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Long Beach :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Los Alamitos : 1160.129.32039 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Los Angeles : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Los Angeles :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Los Angeles : UCLA Stroke Center (Departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center)

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

Los Angeles : University of Southern California

Insulin Resistance Intervention After Stroke Trial

Los Angeles : UCLA Medical Center

Right to Left Cardiac Shunt Detection

Los Angeles : Cedars-Sinai Medical Center

SmartRisk Stroke Prediction by MRI of Carotid Disease

Los Gatos : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Merced : 1160.129.32043 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Mission Viejo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Murrieta :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

National City :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Newport Beach : Hoag Hospital

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

Newport Beach : Hoag Memorial Hospital Presbyterian

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

Northridge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Northridge : 1160.129.32326 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oceanside : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orange :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Orangevale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Palm Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Palmdale :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Palo Alto : Palo Alto Medical Foundation Research Institute

Aspirin in Reducing Events in the Elderly

Palo Alto : 1160.129.32329 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Palo Alto : Stanford University

Insulin Resistance Intervention After Stroke Trial

Paramount :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pasadena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pasadena : US050

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Pasadena : Huntington Memorial Hospital Stroke Center

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

Pomona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pomona :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pomona : 1160.129.32352 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Poway :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rancho Cucamonga :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rancho Mirage : 1160.129.32170 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Redondo Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Redondo Beach :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Riverside :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Roseville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Sacramento : Sutter Memorial Hospital

AMPLATZER Cardiac Plug Clinical Trial

Sacramento : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sacramento :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Sacramento :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Sacramento : University of California-Davis

Insulin Resistance Intervention After Stroke Trial

San Diego : University of California San Diego Division of Neurological Surgery

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

San Diego : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Diego :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

San Diego : 1160.129.32017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

San Diego : University of California

Insulin Resistance Intervention After Stroke Trial

San Francisco : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Francisco : Brain Plasticity Institute

Computerized Attention Training for Individuals With Acquired Brain Injury

San Francisco : California Pacific Medical Center Research Institute

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

San Francisco : University of California

Insulin Resistance Intervention After Stroke Trial

San Francisco : University of California San Francisco Stroke Sciences Group

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

San Francisco : University of California San Francisco

SmartRisk Stroke Prediction by MRI of Carotid Disease

San Jose :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

San Luis Obispo :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

San Ramon :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Santa Ana : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Ana :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Santa Ana : 1160.129.32051 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Santa Clara : Abbott Vascular

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

Santa Rosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Rosa : 1160.129.32330 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Stanford : Stanford University School of Medicine

A Study of Modified Stem Cells in Stable Ischemic Stroke

Stockton : 1160.129.32102 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Temecula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Temecula : 1160.129.32167 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Torrance : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Torrance :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tustin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tustin :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Ventura : 1160.129.32196 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32205 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32249 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Visalia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Visalia : 1160.129.32104 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Vista : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vista :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Walnut Creek : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Westlake Village :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Whittier :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Arvada :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Aurora : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Aurora : 1160.129.32031 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Aurora : University of Colorado

Right to Left Cardiac Shunt Detection

Colorado Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Colorado Springs :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Colorado Springs : 1160.129.32021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Colorado Springs : 1160.129.32204 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Denver : Swedish Medical Center

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

Denver : Endovascular Surgical Neuroradiology, Swedish Medical Center

Assess the Penumbra System in the Treatment of Acute Stroke

Denver : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Denver :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Denver : Denver Health and Hospital Authority

Insulin Resistance Intervention After Stroke Trial

Englewood : Swedish Medical Center

Safety of Intravenous Thrombolysis for Wake-up Stroke

Littleton : 1160.129.32317 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Longmont : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Longmont :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Loveland : Medical Center of the Rockies

AMPLATZER Cardiac Plug Clinical Trial

Wheat Ridge :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Stamford : Stamford Therapeutics Consortium

Are You at Risk for a Heart Attack or Stroke?

Waterbury : Chase Medical Research, LLC

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long Term Outcomes)

Waterbury : Chase Medical Research, LLC

Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes

Bridgeport : 1160.129.32268 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bridgeport : 1160.129.32233 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bridgeport : 1160.129.32193 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Danbury :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fairfield :

BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

Fairfield :

BOTOX® Treatment in Pediatric Upper Limb Spasticity

Fairfield : Merz Investigational Site #001244

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Hartford : Hartford Hospital

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

Hartford : Hartford

Insulin Resistance Intervention After Stroke Trial

Middlebury :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Milford :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Milford : 1160.129.32008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New Haven : Yale University School of Medicine

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

New Haven : Yale University

Insulin Resistance Intervention After Stroke Trial

Norwalk : 1160.129.32074 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Norwalk : 1160.129.32303 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Shelton : 1160.129.32152 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Stamford :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Stamford :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Trumbull :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Newark : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newark : 1160.129.32066 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Washington : Howard University

Aspirin in Reducing Events in the Elderly

Washington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Washington : 1160.129.32202 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Washington : 1160.129.32314 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : Pharmax Research Clinic, Inc.

Do you suffer from Gout and heart problems or diabetes?

St. Petersburg : Comprehensive Clinical Development - St. Petersburg, FL

Gout and a History of Cardiac Disease ITN# 09338

Aventura : 1160.129.32270 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Boca Raton :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Boynton Beach :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Bradenton :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Brandon :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Brandon : 1160.129.32292 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Brandon : 1160.129.32144 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Clearwater : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Clearwater :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Clearwater : 1160.129.32119 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Coral Gables : 1160.129.32304 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Crystal River :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Cutler Bay :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Davie : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Daytona Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Daytona Beach :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Daytona Beach :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Deerfield Beach : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Defuniak Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Delray Beach : 1160.129.32048 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Deltona :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Doral : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Doral : 1160.129.32291 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Edgewater :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fleming Island :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fort Lauderdale :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fort Lauderdale : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Fort Myers :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Gainesville : University of Florida Department of Aging and Geriatrics

Aspirin in Reducing Events in the Elderly

Gainesville : 1160.129.32132 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Gainesville : University of Florida

Insulin Resistance Intervention After Stroke Trial

Hialeah :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Hialeah : 1160.129.32310 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hollywood :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Hollywood :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hollywood : 1160.129.32318 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : 1160.129.32128 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Jacksonville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jacksonville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Jacksonville : University of Florida

Insulin Resistance Intervention After Stroke Trial

Jacksonville Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jupiter : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jupiter : 1160.129.32090 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lakeland : 1160.129.32079 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Melbourne : MIMA Century Research Associates

Insulin Resistance Intervention After Stroke Trial

Miami : Mount Sinai Medical Center

AMPLATZER Cardiac Plug Clinical Trial

Miami : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Miami :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Miami : 1160.129.32212 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32076 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32222 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32124 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32296 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32094 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32276 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : University of Miami

SmartRisk Stroke Prediction by MRI of Carotid Disease

Miami : University of Miami Hospital

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Miami Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Miramar Beach : 1160.129.32125 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Naples : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Smyrna Beach :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

New Smyrna Beach : 1160.129.32005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oakland Park : 1160.129.32147 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oldsmar :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Orlando :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Orlando :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Orlando : 1160.129.32182 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Orlando : Rehabilitation Medical Group - Florida Hospital

SISTERS: Spasticity In Stroke Study - Randomized Study

Panama City : 1160.129.32281 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pembroke Pines :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pembroke Pines : 1160.129.32063 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pensacola : 1160.129.32239 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pensacola :

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

Pinellas Park : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pinellas Park :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pismo Beach : 1160.129.32136 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Port Charlotte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Port Charlotte :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Port Charlotte : 1160.129.32208 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Port Orange : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rockledge : 1160.129.32259 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sarasota :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Sarasota : Sarasota Memorial Hospital

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

Sarasota : 1160.129.32313 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : 1160.129.32006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : 1160.129.32248 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : Intercoastal Medical Group

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Seminole : 1160.129.32020 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

South Miami : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

South Miami :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

St. Cloud :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

St. Petersburg :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

St. Petersburg : 1160.129.32213 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Petersburg : 1160.129.32116 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Petersburg : 1160.129.32057 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Summerfield :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Tallahassee : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tallahassee :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tallahassee : 1160.129.32064 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tamarac :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Tampa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tampa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Tampa : 1160.129.32277 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tampa : Floria Neurovascular Institute

Insulin Resistance Intervention After Stroke Trial

Trinity : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vero Beach : 1160.129.32342 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Wellington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wellington : 1160.129.32037 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

West Palm Beach :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Winter Haven :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Winter Park :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Athens :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Atlanta : Grady Health System

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

Atlanta : Emory University

A Study of Modified Stem Cells in Stable Ischemic Stroke

Atlanta : St. Joseph's Hospital and Research Institute

AMPLATZER Cardiac Plug Clinical Trial

Atlanta : Emory University Hospital and Emory Midtown Hospital

AMPLATZER Cardiac Plug Clinical Trial

Atlanta : Morehouse School of Medicine

Aspirin in Reducing Events in the Elderly

Atlanta : Emory/ Atlanta VAMC

Aspirin in Reducing Events in the Elderly

Atlanta :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Atlanta : US109

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Atlanta : Emory University

Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients

Atlanta : 1160.129.32302 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : 1160.129.32178 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : 1160.129.32253 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Augusta : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Augusta :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Augusta : US042

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Augusta : Georgia Health Sciences University

Study to Examine the Effects of MultiStem in Ischemic Stroke

Calhoun :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Conyers :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Covington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cumming : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cumming : 1160.129.32185 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Decatur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Decatur :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Decatur : 1160.129.32083 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Duluth : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Duluth :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Dunwoody :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Macon : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Roswell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Roswell :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Savannah : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Savannah :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Suwanee :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Honolulu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Honolulu :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Boise :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Boise : Saint Alphonsus Regional Med Center

SISTERS: Spasticity In Stroke Study - Randomized Study

Coeur d'Alene : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Coeur d'Alene :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Coeur d'Alene : 1160.129.32096 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Nampa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Addison :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Arlington Heights :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Arlington Heights : 1160.129.32283 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Belleville : 1160.129.32071 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : Northwestern University Feinberg School of Medicine

A Study of Modified Stem Cells in Stable Ischemic Stroke

Chicago : Rush Alzheimer's Disease Center

Aspirin in Reducing Events in the Elderly

Chicago : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chicago :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Chicago : Rehabilitation Institute of Chicago

Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System

Chicago : 1160.129.32298 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32065 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32103 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32044 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32293 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : Rush University

Insulin Resistance Intervention After Stroke Trial

Chicago : Cook County (Stroger) Hospital

Insulin Resistance Intervention After Stroke Trial

Chicago : University of Illinois

Insulin Resistance Intervention After Stroke Trial

Chicago : Rush University Medical Center

Right to Left Cardiac Shunt Detection

Chicago : Northwestern University

SmartRisk Stroke Prediction by MRI of Carotid Disease

Evanston :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Evanston : US074

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Evergreen Park :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Harvey : Ingalls Memorial Hospital (NINDS-CRC site)

Insulin Resistance Intervention After Stroke Trial

Hinsdale : 1160.129.32117 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Jerseyville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lombard : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Maywood :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Maywood : Loyola University Medical Center

Insulin Resistance Intervention After Stroke Trial

Melrose Park :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Melrose Park : 1160.129.32003 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Morton :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Morton : 1160.129.32133 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Naperville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Peoria : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Peoria : OSF St. Francis Medical Center

Insulin Resistance Intervention After Stroke Trial

Peoria : OSF Stroke Center

IV Double and Triple Concentrated Nicardipine for Stroke and ICH

Quincy :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rock Island : 1160.129.32275 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Rockford :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rockford :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Springfield :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Winfield : Central DuPage Hospital

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Anderson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bloomington :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Bloomington : 1160.129.32106 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Brownsburg : 1160.129.32001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Elkhart : Indiana Medical Research

Insulin Resistance Intervention After Stroke Trial

Evansville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fort Wayne : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Hammond : 1160.129.32046 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Indianapolis : St Vincent Heart Center of Indiana

AMPLATZER Cardiac Plug Clinical Trial

Indianapolis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Indianapolis : US016

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Indianapolis : Clarian Health / Methodist Hospital

Exclusion of the Left Atrial Appendage (LAA) With the LAAx, Inc. TigerPaw System

Indianapolis : 1160.129.32245 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

La Porte : 1160.129.32320 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lafayette :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Newburgh : 1160.129.32210 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

South Bend : 1160.129.32327 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Valparaiso :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Valparaiso : Associates In Neurology (NINDS-CRC site)

Insulin Resistance Intervention After Stroke Trial

Ames : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ames : 1160.129.32042 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Des Moines : US072

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Des Moines : Ruan Neuroscience Center/Mercy Medical Center

Insulin Resistance Intervention After Stroke Trial

Des Moines : Iowa Health Des Moines Clinical Trials Office

Insulin Resistance Intervention After Stroke Trial

Iowa City : University of Iowa

Aspirin in Reducing Events in the Elderly

Iowa City : University of Iowa

Insulin Resistance Intervention After Stroke Trial

Waterloo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Waterloo : 1160.129.32055 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Waterloo : Northeast Iowa Medical Education Foundation (NINDS-CRC site)

Insulin Resistance Intervention After Stroke Trial

West Des Moines : 1160.129.32089 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Wichita : Via Christi Research

THERAPY: Assess the Penumbra System to Treat Acute Stroke

Kansas City : Kansas University Medical Center

Aspirin in Reducing Events in the Elderly

Kansas City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kansas City : 1160.129.32341 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lenexa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Overland Park : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Overland Park :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Overland Park : Merz Investigational Site # 001110

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Overland Park : 1160.129.32029 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Topeka : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Topeka :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Wichita : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wichita :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Wichita : Via Christi Regional Medical Center

Insulin Resistance Intervention After Stroke Trial

Lexington : University of Kentucky Chandler Medical Center Updated

Rehabilitation: Have You or Someone You Know Experienced a Stroke?

Lexington : University of Kentucky Chandler Medical Center Updated

Stroke: Research Study Have You or Someone You Know Experienced a Stroke?

Bowling Green : 1160.129.32010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Elizabethtown :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Elizabethtown : 1160.129.32025 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lexington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lexington :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lexington : University of Kentucky Research Foundation

Insulin Resistance Intervention After Stroke Trial

Louisville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Louisville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Louisville : University of Louisville

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

Mount Sterling : 1160.129.32188 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Owensboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Owensboro :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Owensboro : 1160.129.32059 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Paducah :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Alexandria : 1160.129.32176 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Baton Rouge : Pennington Biomedical Research Center

Aspirin in Reducing Events in the Elderly

Baton Rouge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Baton Rouge : 1160.129.32286 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bossier City : 1160.129.32201 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Covington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Eunice : 1160.129.32129 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hammond : 1160.129.32045 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kenner : 1160.129.32271 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lafayette : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lafayette : 1160.129.32056 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32169 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32214 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32235 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Mandeville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mer Rouge :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Metairie : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Monroe :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

New Orleans : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Orleans : 1160.129.32274 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Opelousas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shreveport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shreveport :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Shreveport : Louisiana State University Health Sciences Center

Insulin Resistance Intervention After Stroke Trial

Slidell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Slidell : 1160.129.32164 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Winnsboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Zachary : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beltsville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Biddeford :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Biddeford : 1160.129.32122 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Portland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rockport :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rockport : Penobscot Bay Neurology

Insulin Resistance Intervention After Stroke Trial

Baltimore : Spectrum Clinical Research, Inc.

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)

Baltimore : Spectrum Clinical Research, Inc.

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Annapolis : 1160.129.32226 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Baltimore :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Baltimore : US014

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Baltimore : 1160.129.32207 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : 1160.129.32228 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : Johns Hopkins

Insulin Resistance Intervention After Stroke Trial

Baltimore : Sinai Hospital of Baltimore

Insulin Resistance Intervention After Stroke Trial

Baltimore : The Johns Hopkins Hospital

Safety of Intravenous Thrombolytics in Stroke on Awakening

Baltimore : Johns Hopkins Hospital

Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke

Baltimore : Johns Hopkins Bayview Medical Center

Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbia : Howard County General Hospital

Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke

Cumberland :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Glen Burnie : 1160.129.32247 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hagerstown :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lutherville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oxon Hill :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rockville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salisbury : 1160.129.32148 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salisbury : 1160.129.32155 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : Merz Investigational Site #001210

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Takoma Park : 1160.129.32256 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Towson : 1160.129.32229 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Wheaton :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Haverhill : ActivMed Practices & Research, Inc. Updated

Previous heart attack or stroke?Cardiovascular disease? Diabetes? Raised blood sugar levels?

Haverhill : ActivMed Practices & Research, Inc. Updated

Would you be interested in taking part in a type 2 diabetes research study?

Haverhill : ActivMed Practices & Research, Inc. Updated

You may qualify to participate in a clinical research study testing an investigational medication for Type II Diabetes

Ayer : 1160.129.32203 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Boston : US039

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Boston : US003

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Boston : Massachusetts General Hospital

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Boston : Massachusetts General Hospital

Insulin Resistance Intervention After Stroke Trial

Boston : Boston University

Insulin Resistance Intervention After Stroke Trial

Boston : Beth Israel Deaconess

Insulin Resistance Intervention After Stroke Trial

Boston : Tufts Medical Center

Right to Left Cardiac Shunt Detection

Boston : Tufts Medical Center

SmartRisk Stroke Prediction by MRI of Carotid Disease

Boston : Beth Israel Deaconess Medical Center

SmartRisk Stroke Prediction by MRI of Carotid Disease

Boston : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Brockton :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Burlington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charlestown : Myomo Inc

Myomo e100 NeuroRobotic System Home Safety Study

Fall River : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fall River :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fall River : 1160.129.32013 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Haverhill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyannis :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Natick : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Natick : 1160.129.32294 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Newton : 1160.129.32289 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Worcester :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Worcester : UMASS Medical Center

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Alpena : 1160.129.32036 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ann Arbor : University of Michigan

Aspirin in Reducing Events in the Elderly

Ann Arbor : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ann Arbor :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Ann Arbor :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Bay City : 1160.129.32234 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bingham Farms :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Chelsea : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chelsea :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Detroit : Wayne State University

Aspirin in Reducing Events in the Elderly

Detroit :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Detroit : 1160.129.32135 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Detroit : Wayne State University

SmartRisk Stroke Prediction by MRI of Carotid Disease

Detroit : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

East Lansing : Michigan State University

SmartRisk Stroke Prediction by MRI of Carotid Disease

Erie : 1160.129.32340 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Flint :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Flint : 1160.129.32047 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Grand Blanc : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Grand Blanc : 1160.129.32264 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Grand Blanc : 1160.129.32168 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Grand Rapids : Spectrum Health

AMPLATZER Cardiac Plug Clinical Trial

Grand Rapids : US078

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Kalamazoo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kalamazoo :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lansing :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lansing : 1160.129.32052 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Marquette : 1160.129.32142 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Midland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mount Clemens : 1160.129.32232 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Niles : 1160.129.32053 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Novi : Detroit Clinical Research Center

Aspirin in Reducing Events in the Elderly

Novi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Novi : 1160.129.32282 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Petoskey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rochester : 1160.129.32134 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Royal Oak : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Royal Oak : US113

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Saginaw : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saginaw : 1160.129.32231 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Saginaw : 1160.129.32075 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Southfield : Providence Hospital

AMPLATZER Cardiac Plug Clinical Trial

Troy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wyoming : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bloomington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brooklyn Center :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Chaska :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Chaska : 1160.129.32024 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Duluth : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Duluth :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Edina : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Edina :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Golden Valley : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Minneapolis : Health Partners Research Foundation

Aspirin in Reducing Events in the Elderly

Minneapolis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Minneapolis : 1160.129.32280 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Minneapolis : Minneapolis Heart Institute

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Robbinsdale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Robbinsdale : Minneapolis Clinic of Neurology

Insulin Resistance Intervention After Stroke Trial

Robbinsdale : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Saint Paul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Cloud : St. Cloud Hospital/CentraCare Heart and Vascular Clinic

AMPLATZER Cardiac Plug Clinical Trial

St. Cloud : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Cloud : 1160.129.32190 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Paul : St. Joseph Hospital- Healtheast

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

St. Paul : HealthEast St. Joseph's Hospital

AMPLATZER Cardiac Plug Clinical Trial

St. Paul : Phalen Village Clinic

Aspirin in Reducing Events in the Elderly

St. Paul : 1160.129.32307 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Biloxi : 1160.129.32339 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hattiesburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jackson :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Jackson :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Olive Branch :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Picayune : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Port Gibson :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Chesterfield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Clarkson Valley :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbia : Merz Investigational Site #001209

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Florissant :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Kansas City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kansas City :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Springfield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Charles :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

St. Louis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Louis :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

St. Louis : 1160.129.32143 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : 1160.129.32101 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : 1160.129.32184 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : 1160.129.32297 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : Washington University

Insulin Resistance Intervention After Stroke Trial

St. Louis : St. Louis University

Insulin Resistance Intervention After Stroke Trial

Washington :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Billings :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Billings : Billings Clinic

Insulin Resistance Intervention After Stroke Trial

Butte :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Great Falls : Advanced Neurology Specialists

Insulin Resistance Intervention After Stroke Trial

Kalispell : 1160.129.32165 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bellevue :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Grand Island : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Grand Island :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lincoln : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lincoln :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lincoln :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Omaha : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Omaha :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Omaha : 1160.129.32321 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Omaha : 1160.129.32331 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Omaha : University of Nebraska

Insulin Resistance Intervention After Stroke Trial

Papillion : 1160.129.32199 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Henderson :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Las Vegas :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Reno :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Reno : 1160.129.32180 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Newington : ActivMed Practices & Research, Inc. NH Updated

Previous heart attack or stroke, cardiovascular disease, Diabetes or Raised blood sugar levels?

Lebanon : US077

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Lebanon : Dartmouth Hitchcock Medical Center

Insulin Resistance Intervention After Stroke Trial

Nashua : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brick :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Bridgewater :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Bridgewater : 1160.129.32154 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Camden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Camden : Cooper University Hospital

Insulin Resistance Intervention After Stroke Trial

Edison :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Edison : US055

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Elizabeth : Central Jersey Medical Center

Aspirin in Reducing Events in the Elderly

Elmer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Englewood : 1160.129.32181 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Freehold : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haddon Heights : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haddon Heights : 1160.129.32179 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hammonton : 1160.129.32198 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Linden : 1160.129.32030 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lumberton :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Manalapan :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Medford :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Morristown : 1160.129.32324 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Neptune : 1160.129.32049 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New Brunswick : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ocean : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ocean : 1160.129.32242 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Paterson : 1160.129.32255 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pomona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ridgewood : US100

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Ridgewood : 1160.129.32221 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Saddle Brook : Kessler Institute for Rehabilitation

Study of Robot-assisted Arm Therapy for Acute Stroke Patients

Somerset : 1160.129.32099 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

South Plainfield : 1160.129.32007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Stratford : Merz Investigational Site #001198

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Voorhees : 1160.129.32069 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

West Orange : Kessler Foundation Research Center

Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System

West Orange : 1160.129.32269 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

West Orange : Kessler Medical Rehab Research Corp

Insulin Resistance Intervention After Stroke Trial

Westwood : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Albuquerque : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Albuquerque :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Albuquerque :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Albuquerque : 1160.129.32311 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Albuquerque : University of New Mexico

Insulin Resistance Intervention After Stroke Trial

New Hyde Park : Biomedical Research Alliance of New York

Stroke- Micardis

Albany : US075

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Albany : 1160.129.32332 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Albany : Albany Medical Center

Insulin Resistance Intervention After Stroke Trial

Binghamton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bronx :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Bronx : 1160.129.32173 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bronxville : 1160.129.32084 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Brooklyn : 1160.129.32246 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Brooklyn : SUNY Downstate

Insulin Resistance Intervention After Stroke Trial

Brooklyn : New York Methodist Hospital

Insulin Resistance Intervention After Stroke Trial

Buffalo : Kaleida Health

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

Buffalo : US012

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Buffalo :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Buffalo : SUNY Buffalo

Insulin Resistance Intervention After Stroke Trial

Buffalo : Kaleida Health/Buffalo General

Solitaire™ FR as Primary Treatment for Acute Ischemic Stroke

Buffalo : Millard Fillmore Gates Circle Hospital

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

Endwell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Endwell :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Freeport :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Glens Falls :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Huntington : 1160.129.32195 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Johnson City : 1160.129.32278 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Mineola : Winthrop University Hospital

Aspirin in Reducing Events in the Elderly

Mineola : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mineola :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Mineola : 1160.129.32038 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New Windsor : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Windsor :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

New York : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New York : Columbia University Medical Center

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

New York : 1160.129.32110 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New york : Columbia University Medical Center

Right to Left Cardiac Shunt Detection

New York : New York University School of Medicine

SmartRisk Stroke Prediction by MRI of Carotid Disease

New York : Gotham Cardiovascular Research PC

SmartRisk Stroke Prediction by MRI of Carotid Disease

New York : New York University School of Medicine

Study of Botulinum Toxin and Recovery of Hand Function After Stroke

Plainview : Merz Investigational Site #001207

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Poughkeepsie :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rochester : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rochester :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rochester :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Rochester : University of Rochester

Insulin Resistance Intervention After Stroke Trial

Stony Brook : Stony Brook University Hospital

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

Syracuse : 1160.129.32139 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Syracuse : 1160.129.32015 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

West Seneca :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

West Seneca : Southtowns Neurology of WNY (NINDS-CRC site)

Insulin Resistance Intervention After Stroke Trial

Westfield :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Westfield : 1160.129.32263 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

White Plains : Burke Medical Research Institute

Insulin Resistance Intervention After Stroke Trial

Williamsville : 1160.129.32016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Williamsville : 1160.129.32209 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Greensboro : Guilford Neurologic Associates

Do you have foot drop as a result of a stroke?

Greensboro : Guilford Neurologic Associates

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Greensboro : Guilford Neurologic Associates

Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)

Greensboro : Guilford Neurologic Associates

Insulin Resistance Intervention After Stroke Trial (IRIS)

Greensboro : Guilford Neurologic Associates

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Raleigh : PMG Research of Raleigh

Heart Attack...Stroke. Are you at risk?

Winston-Salem : PMG Research of Winston-Salem

Have you had a stroke? Have you experienced difficulty walking since your stroke?

Asheboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Asheboro :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Asheboro : 1160.129.32194 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Burlington : 1160.129.32265 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Calabash : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cary :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Charlotte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charlotte :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Durham : Duke University Medical Center

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Greensboro : Wake Forest University Baptist Medical Center

Aspirin in Reducing Events in the Elderly

Greensboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greensboro :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Greensboro : US037

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Greensboro : 1160.129.32022 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Greenville : The Brody School of Medicine at ECU

Aspirin in Reducing Events in the Elderly

Greenville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Harrisburg :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Hickory : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hickory : 1160.129.32070 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

High Point : 1160.129.32033 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Huntersville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Jacksonville : 1160.129.32114 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kannapolis : 1160.129.32251 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lenoir :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lenoir : 1160.129.32072 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Monroe :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pinehurst : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pinehurst : 1160.129.32073 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Raleigh :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Raleigh : 1160.129.32162 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salisbury : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salisbury :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Sanford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shelby :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Statesville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wilmington :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Wilson : 1160.129.32215 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Winston-Salem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Winston-Salem :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Winston-Salem : Merz Investigational Site #001009

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Winston-Salem : Clinical Research of Winston-Salem

Insulin Resistance Intervention After Stroke Trial

Winston-Salem : Guilford Neurologic Associates

Insulin Resistance Intervention After Stroke Trial

Fargo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fargo :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fargo : 1160.129.32118 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Grand Forks : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Grand Forks : Altru Health System

Insulin Resistance Intervention After Stroke Trial

Minot : 1160.129.32220 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Akron : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Akron :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Canton :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Centerville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Cincinnati : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cincinnati :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Cincinnati : University of Cincinnati

Insulin Resistance Intervention After Stroke Trial

Cincinnati : Drake Rehabilitation Center

Navigated Transcranial Magnetic Stimulation in Monitoring Stroke Recovery

Cleveland : University Hospitals Case Medical Center

AMPLATZER Cardiac Plug Clinical Trial

Cleveland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cleveland : MetroHealth Medical Center

Electrical Stimulation for the Treatment of Post-Stroke Shoulder Pain

Cleveland : 1160.129.32273 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Cleveland : Case Western Reserve University

Insulin Resistance Intervention After Stroke Trial

Cleveland : Metrohealth Medical Center

Insulin Resistance Intervention After Stroke Trial

Cleveland : Cleveland Clinic Foundation

Insulin Resistance Intervention After Stroke Trial

Cleveland : University Hospitals of Cleveland

Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions

Columbus : The Ohio State University

AMPLATZER Cardiac Plug Clinical Trial

Columbus : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbus :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Columbus : The Ohio State University

Cryptogenic Stroke Study

Columbus : Ohio State University

Insulin Resistance Intervention After Stroke Trial

Columbus : Riverside Hospital

Right to Left Cardiac Shunt Detection

Columbus : Ohio Health Research Institute

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Dayton :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Delaware :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fairfield : 1160.129.32257 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fairview Park : 1160.129.32061 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Franklin :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Gallipolis : 1160.129.32011 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hudson : 1160.129.32060 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kettering :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Kettering : 1160.129.32183 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lyndhurst :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Marion : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Marion :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Marion : 1160.129.32316 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Marion : 1160.129.32158 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Mentor :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Miamisburg : 1160.129.32012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Middleburg Heights :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Perrysburg :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Springfield : 1160.129.32244 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toledo :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Toledo : 1160.129.32285 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toledo : ProMedica Toledo Hospital

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Toledo : University of Toledo

Insulin Resistance Intervention After Stroke Trial

Willoughby Hills :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Youngstown : 1160.129.32032 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bartlesville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oklahoma City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oklahoma City :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Oklahoma City : 1160.129.32258 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oklahoma City : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Tulsa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tulsa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Ashland :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Bend : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bend :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Eugene :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Portland : Oregon Health and Science University

AMES Treatment of the Impaired Leg in Chronic Stroke Patients

Portland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Portland :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Portland : 1160.129.32163 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Portland : Oregon Health & Science University

Insulin Resistance Intervention After Stroke Trial

Portland : GSK Investigational Site Updated

POC in Patients With Ischaemic Stroke

Abington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Allentown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Altoona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Altoona :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Beaver : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bensalem :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Bethlehem :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Bryn Mawr : Lankenau Institute for Medical Research

Insulin Resistance Intervention After Stroke Trial

Butler :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Camp Hill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Camp Hill : 1160.129.32236 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Carnegie : 1160.129.32086 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chambersburg : 1160.129.32206 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Downingtown :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Doylestown :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Doylestown : 1160.129.32157 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Duncansville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Elkins Park : Einstein Hospital/Moss Rehabilitation

SISTERS: Spasticity In Stroke Study - Randomized Study

Ephrata :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Erie : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Feasterville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Harleysville : 1160.129.32113 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hershey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hershey : Penn Stat-Hershey Medical Center (NINDS-CRC site)

Insulin Resistance Intervention After Stroke Trial

Hershey : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Hummelstown : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Jersey Shore : 1160.129.32127 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lansdale :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lansdale : 1160.129.32153 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Penndel : 1160.129.32115 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Philadelphia : University of Pennsylvania

AMPLATZER Cardiac Plug Clinical Trial

Philadelphia : Albert Einstein Medical Center

Aspirin in Reducing Events in the Elderly

Philadelphia :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Philadelphia :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Philadelphia : 1160.129.32323 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Philadelphia : 1160.129.32337 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Philadelphia : University of Pennsylvania Medical Center

GORE® HELEX® Septal Occluder / GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study

Philadelphia : Temple University

Insulin Resistance Intervention After Stroke Trial

Pittsburgh : University of Pittsburgh Medical Center

A Study of Modified Stem Cells in Stable Ischemic Stroke

Pittsburgh : University of Pittsburgh Health Sciences Research Center

Aspirin in Reducing Events in the Elderly

Pittsburgh : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pittsburgh :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pittsburgh : US084

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Pittsburgh : Allegheny Singer Research Institute

Insulin Resistance Intervention After Stroke Trial

Pittsburgh : University of Pittsburgh Medical Center Presbyterian Hospital

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Pottstown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Quakertown :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Sellersville : 1160.129.32192 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tipton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Uniontown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Warminster : 1160.129.32109 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Wyomissing :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Yardley : 1160.129.32137 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

York : York Hospital

AMPLATZER Cardiac Plug Clinical Trial

Cranston :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Cumberland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cumberland :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

East Providence :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pawtucket : Memorial Hospital of Rhode Island

Aspirin in Reducing Events in the Elderly

Pawtucket : 1160.129.32224 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pawtucket : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Providence : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Providence :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Providence : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Mt. Pleasant : PMG Research of Charleston

Have you suffered from a heart attack or stroke?

Anderson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Anderson :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Anderson : 1160.129.32243 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Anderson : 1160.129.32160 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Beaufort : 1160.129.32002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Charleston : Roper Hospital/PMG Research of Charleston

AMPLATZER Cardiac Plug Clinical Trial

Charleston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charleston :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbia :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Columbia : US057

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Columbia : 1160.129.32050 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Columbia : Palmetto Health Richland

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Greenville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greenville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Greenwood :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Greer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greer :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Mt. Pleasant : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Murrells Inlet :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Myrtle Beach :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Myrtle Beach : 1160.129.32108 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ninety Six : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

North Myrtle Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orangeburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orangeburg :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Pelzer :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Rock Hill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rock Hill :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Simpsonville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Spartanburg :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Varnville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rapid City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rapid City :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rapid City : 1160.129.32267 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sioux Falls : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bristol : PMG Research of Bristol

Heart Attack...Stroke. Are you at risk?

Athens :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Chattanooga :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Chattanooga : US019

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Chattanooga : Erlanger Health care system

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

Chattanooga : 1160.129.32217 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chattanooga : Erlanger Stroke Center

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Clarksville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Collierville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fayetteville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Germantown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jackson :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Jackson : 1160.129.32338 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Johnson City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Johnson City : 1160.129.32272 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kingsport :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Kingsport : 1160.129.32343 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Knoxville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Knoxville : 1160.129.32082 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Knoxville : 1160.129.32080 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Knoxville : 1160.129.32287 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Memphis : University of Tennessee Health Science Center

Aspirin in Reducing Events in the Elderly

Memphis :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Memphis :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Nashville : Vanderbilt University Medical Center

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

Nashville : Merz Investigational Site #001206

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Nashville : US058

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Nashville : 1160.129.32186 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Nashville : Vanderbilt

Insulin Resistance Intervention After Stroke Trial

Nashville : Vanderbilt Univiersity

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

New Tazewell :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

New Tazewell : 1160.129.32223 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Allen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Allen :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Austin : 1160.129.32145 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Austin : University Medical Center at Brackenridge

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Beaumont : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beaumont : 1160.129.32095 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bedford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Carrollton :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Dallas : University of Texas Southwestern Medical Center at Dallas

Aspirin in Reducing Events in the Elderly

Dallas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dallas :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Dallas : 1160.129.32322 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Dallas : 1160.129.32252 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Dallas : 1160.129.32290 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Dallas : University of Texas, Southwestern

Insulin Resistance Intervention After Stroke Trial

DeSoto :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

El Paso :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fort Worth :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Fort Worth : 1160.129.32300 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fort Worth : 1160.129.32097 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fort Worth : 1160.129.32315 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Galveston : University of TX Medical Branch

Aspirin in Reducing Events in the Elderly

Gonzales : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Grapevine :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Grapevine : 1160.129.32105 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Houston :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Houston : Merz Investigational Site #001183

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Houston : US021

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Houston : 1160.129.32123 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32092 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32100 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32295 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32301 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32111 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32027 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : The Methodist Hospital System

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Houston : Methodist Neurological Institute

Insulin Resistance Intervention After Stroke Trial

Houston : Methodist DeBakey Heart and Vascular Center

Right to Left Cardiac Shunt Detection

Houston : UT-Houston Health Science Center

Safety of Intravenous Thrombolysis for Wake-up Stroke

Houston : Baylor College of Medicine

SmartRisk Stroke Prediction by MRI of Carotid Disease

Houston : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Houston : The University of Texas Medical School

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Humble : 1160.129.32219 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Irving : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Irving :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Katy : 1160.129.32171 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kingwood : 1160.129.32211 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leander : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Livingston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lubbock : 1160.129.32260 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lufkin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Marshall : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

McKinney : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nassau Bay :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

New Braunfels :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

New Braunfels : 1160.129.32189 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

North Richland Hills : 1160.129.32177 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Odessa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Odessa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Odessa : 1160.129.32197 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pasadena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plano : Texas Stroke Institute

A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial

Plano : The Heart Hospital Baylor

AMPLATZER Cardiac Plug Clinical Trial

Plano : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plano :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Richardson :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

San Antonio : UT Health Science Center at San Antonio

Aspirin in Reducing Events in the Elderly

San Antonio : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Antonio :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

San Antonio : 1160.129.32238 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

San Antonio : 1160.129.32187 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sealy : 1160.129.32288 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Seguin : 1160.129.32191 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Southlake :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Sugar Land :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Sugar Land : 1160.129.32068 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sugar Land : 1160.129.32040 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Temple : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Temple : 1160.129.32336 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

The Woodlands : 1160.129.32319 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tomball :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Tomball : 1160.129.32091 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tyler :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tyler : 1160.129.32306 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Waco : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Waco :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Waco : 1160.129.32334 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Waco : 1160.129.32093 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Webster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Whitney : 1160.129.32175 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bountiful : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bountiful :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Draper :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Layton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Layton :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Salt Lake City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salt Lake City :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Salt Lake City : 1160.129.32034 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salt Lake City : 1160.129.32121 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salt Lake City : University of Utah

Insulin Resistance Intervention After Stroke Trial

Salt Lake City : Western Institute for Biomedical Research

SmartRisk Stroke Prediction by MRI of Carotid Disease

West Jordan :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Burlington : University of Vermont

Insulin Resistance Intervention After Stroke Trial

Alexandria :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Arlington :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Burke : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Burke :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Burke : 1160.129.32166 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Charlottesville : University of Virginia

Insulin Resistance Intervention After Stroke Trial

Chesapeake : 1160.129.32004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Danville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Danville :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Danville : 1160.129.32067 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ettrick : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Falls Church : 1160.129.32146 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Harrisonburg : James Madison University and Rockingham Memorial Hospital

The Passy Muir Swallowing Self Training Device to Enhance Recovery Post Stroke

Manassas :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Manassas : 1160.129.32328 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Manassas : 1160.129.32200 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Midlothian : 1160.129.32279 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Norfolk :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Norfolk : Sentara Medical Group

Insulin Resistance Intervention After Stroke Trial

Richmond : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Richmond :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Virginia Beach :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Lynnwood : Clinical Trials of America, Inc

Are you experiencing deficits post ischemic stroke?

Burien : 1160.129.32062 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Port Orchard : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Port Orchard :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Port Orchard : 1160.129.32227 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Redmond : Cerevast Therapeutics, Inc.

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

Renton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seattle : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seattle :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Seattle : 1160.129.32241 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Seattle : Swedish Medical Center

Right to Left Cardiac Shunt Detection

Seattle : Swedish Medical Center, Cherry Hill Campus

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Silverdale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tacoma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tacoma :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Clarksburg :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Huntington : 1160.129.32028 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Morgantown : 1160.129.32333 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Morgantown : West Virginia University

SmartRisk Stroke Prediction by MRI of Carotid Disease

Green Bay :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

La Crosse : 1160.129.32308 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Madison : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Madison :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Madison : University of Wisconsin

Insulin Resistance Intervention After Stroke Trial

Milwaukee :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Milwaukee : US097

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Milwaukee : 1160.129.32058 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32041 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32325 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32088 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : Medical College of Wisconsin

Insulin Resistance Intervention After Stroke Trial

Oregon :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Wausau : Aspirus Heart & Vascular Institute

AMPLATZER Cardiac Plug Clinical Trial

Wausau :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Wauwatosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wauwatosa :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Weston :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Bahía Blanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Buenos Aires : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Buenos Aires : 1160.129.21008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Buenos Aires : 1160.129.21009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Buenos Aires : 1160.129.21012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Caba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Caba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Capital Federal : 1160.129.21007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Cipolletti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cordoba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Córdoba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Corrientes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Corrientes : 1160.129.21006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Formosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Godoy Cruz : 1160.129.21010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Mar del Plata : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Posadas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Quilmes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rosario : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Jose Gaymallen : 1160.129.21002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

San Luis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Miguel de Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Nicolas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Salvador de Jujuy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Fe : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santiago del Estero : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bateman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bedford Park : Flinders Medical Centre

Insulin Resistance Intervention After Stroke Trial

Box Hill : Box Hill Hospital (Eastern Health)

Insulin Resistance Intervention After Stroke Trial

Brisbane : Princess Alexandra Hospital

A Clinical Trial of IntensiVE Dialysis

Camperstown : Royal Prince Alfred

Insulin Resistance Intervention After Stroke Trial

Clayton : AU006

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Clayton :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Footscray : Western Hospital (University of Melbourne)

Insulin Resistance Intervention After Stroke Trial

Garran : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Geelong : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gold Coast : Gold Coast Hospital

A Clinical Trial of IntensiVE Dialysis

Gosford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gosford : AU004

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Heidelberg : Heidelberg Repatriation Hospital, Melbourne

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Heidelberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heidelberg Heights : Austin Health (National Stroke Research Institute)

Insulin Resistance Intervention After Stroke Trial

Hobart : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Joondalup : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kogarah : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Liverpool : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Melbourne : Monash Medical Centre

A Clinical Trial of IntensiVE Dialysis

Melbourne : Royal Melbourne Hospital

A Clinical Trial of IntensiVE Dialysis

Melbourne : AU002

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Melbourne : AU001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Milton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nambour : Nambour General Hospital

A Clinical Trial of IntensiVE Dialysis

New Castle : AU003

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

New Lambton Heights :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

New Lambton Heights : John Hunter Hospital (University of Newcastle)

Insulin Resistance Intervention After Stroke Trial

Parkville : Royal Melbourne Hospital

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Parkville :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Parkville : Royal Melbourne Hospital

Insulin Resistance Intervention After Stroke Trial

Perth : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Perth : Royal Perth

Insulin Resistance Intervention After Stroke Trial

Southport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sydney : Sydney Dialysis Centre

A Clinical Trial of IntensiVE Dialysis

Sydney : Statewide Renal Services

A Clinical Trial of IntensiVE Dialysis

Sydney : Liverpool Hospital

A Clinical Trial of IntensiVE Dialysis

Feldbach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Graz : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Graz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Graz : AT003

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Graz : Marianne Brodmann

Global Anticoagulant Registry in the Field

Graz : Universitätsklinikum für Neurologie

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Innsbruck : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Innsbruck : AT004

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Innsbruck :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Innsbruck : 1160.136.34002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Linz : O.O. Landes-Nervenklinik Wagner-Jauregg

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Linz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Linz : AT001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Linz : 1160.136.34001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Moedling : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Neupölla : 1160.136.34005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Oberwart : 1160.136.34008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Salzburg : Christian-Doppler-Klinik Salzburg,Universitätsklinik für Neurologie

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Salzburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Stefan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vienna : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vienna : Sozialmedizinisches Zentrum Baumgartner Höhe Otto-Wagner-Spital

SISTERS: Spasticity In Stroke Study - Randomized Study

Wien : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Wien : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wien : Merz Investigational Site #043003

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Wien :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Wien : 1160.136.34004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Zirl : Landeskrankenhaus Hochzirl

SISTERS: Spasticity In Stroke Study - Randomized Study

Zwettl : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Grodno : Nycomed Investigational Site

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Minsk : Nycomed Investigational Site

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Vitebsk : Nycomed Investigational Site

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Aalst : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bonheiden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brasschaat : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brussel : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brussels : Cliniques Universitaires Saint Luc

Effect of F2695 on Functional Recovery After Ischemic Stroke

Bruxelles : Clin. Univ. UCL Saint Luc

SISTERS: Spasticity In Stroke Study - Randomized Study

Bruxelles - Brussel :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

De Pinte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dendermonde : AZ Sint Blasius Hospital, Department of Vascular Surgery

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Genk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gent : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gent : Universitair Ziekenhuis Gent

SISTERS: Spasticity In Stroke Study - Randomized Study

Ghent : Drug Research Unit Ghent

A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.

Ghent : Universitair Ziekenhuis Gent

Effect of F2695 on Functional Recovery After Ischemic Stroke

Gilly :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hasselt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hasselt :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Huy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leuven : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leuven :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Leuven : Universitaire Ziekenhuizen Leuven, campus Pellenberg

SISTERS: Spasticity In Stroke Study - Randomized Study

Liege : Clinique Saint-Joseph

Effect of F2695 on Functional Recovery After Ischemic Stroke

Liege :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Mechelen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

MOL :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Ottignies : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tielt : Sint-Andriesziekenhuis

Effect of F2695 on Functional Recovery After Ischemic Stroke

Tienen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Aracajú : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belo Horizonte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belo Horizonte : 1160.129.22012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Belo Horizonte : 1160.129.22011 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Blumenau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Blumenau : 1160.129.22029 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Brasilia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brasilia : 1160.129.22004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Campinas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Campinas : BR012

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Campinas : 1160.129.22017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Campo Grande : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Curitiba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Curitiba : 1160.129.22016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Goiania : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Maceio : 1160.129.22024 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Passo Fundo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Passo Fundo : 1160.129.22021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pelotas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Porto Alegre : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Porto Alegre : BR008

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Porto Alegre : BR007

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Porto Alegre : 1160.129.22006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Porto Alegre : 1160.129.22005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Porto Alegre : 1160.129.22026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Recife : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rio de Janeiro : BR011

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Rio de Janeiro : BR009

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Salvador : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salvador : BR006

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Salvador : 1160.129.22023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salvador : 1160.129.22002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Santo Andre : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santo Andre : 1160.129.22007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sao Jose do Rio Preto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sao Jose do Rio Preto : 1160.129.22001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sao Paulo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sao Paulo : 1160.129.22018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sao Paulo : 1160.129.22008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sao Paulo : 1160.129.22003 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

São Paulo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

São Paulo : University of São Paulo - Hospital das Clínicas

Motor Cortex Stimulation for Chronic Neuropathic Pain

São Paulo : Instituto de Ensino e Pesquisa do Hospital do Coração (IEP-HCor)

Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)

Tatui : 1160.129.22032 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Uberlândia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Votuporanga : 1160.129.22025 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Burgas : 1160.136.36004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Kazanlak : 1160.136.36002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Pazardzhik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pleven : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pleven : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Plovdiv : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plovdiv : 1160.136.36008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Rousse : 1160.136.36005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sevlievo : 1160.136.36001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sliven : 1160.136.36013 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sofia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sofia : 1160.136.36011 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sofia : 1160.136.36012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sofia : 1160.136.36014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sofia : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Stara Zagora : 1160.136.36009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Varna : 1160.136.36015 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Yambol : 1160.136.36006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Antigonish : 1160.129.06010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Brampton, ON :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Calgary : CA001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Calgary : 1160.129.06018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Cambridge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cambridge : 1160.129.06023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicoutimi : 1160.129.06024 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Coquitlam : 1160.129.06005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Downsview : 1160.129.06003 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Drummondville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Edmonton : CA004

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Edmonton :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Edmonton : 1160.129.06004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Edmonton : University of Alberta

Insulin Resistance Intervention After Stroke Trial

Edmonton : GSK Investigational Site Updated

POC in Patients With Ischaemic Stroke

Edmonton, AB :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Gatineau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Granby : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greenfield Park : Hôpital Charles LeMoyne

Insulin Resistance Intervention After Stroke Trial

Grimsby : 1160.129.06020 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Halifax : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Halifax : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Halifax : Merz Investigational Site #001204

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Halifax : 1160.129.06025 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Halifax : QE II Health Sciences Centre

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Hamilton :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hamilton : 1160.129.06032 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hamilton : 1160.129.06016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hamilton : Hamilton Health Sciences Corporation-General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Hamilton : Hamilton Health Sciences Corporation-McMaster Site

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Hamilton : Hamilton Health Sciences Corporation-Henderson Site

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Hamilton :

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Hamilton : Saint Joseph's Healthcare

Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)

Hamilton : Health Science Centre, McMaster University

Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)

Hamilton, ON :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Joliette : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kelowna : 1160.129.06027 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kitchener : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lachine : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Langley, BC :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Laval : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lethbridge : Center for Neurologic Research

Insulin Resistance Intervention After Stroke Trial

Levis : 1160.129.06014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lévis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

London : Robarts Research Institute

Insulin Resistance Intervention After Stroke Trial

London, ON :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Longueuil : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Loretteville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Mississauga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

MIssissauga : 1160.129.06028 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Montreal : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Montreal :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Montreal : 1160.129.06009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Montreal : McGill-Jewish General

Insulin Resistance Intervention After Stroke Trial

Montreal : CHUM-Centre de recherche, Hôpital Notre-Dame

Insulin Resistance Intervention After Stroke Trial

Montreal : McGill-Montreal General

Insulin Resistance Intervention After Stroke Trial

Montreal : SMBD Jewish General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Montreal : Montreal General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Mount Pearl : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Westminster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newmarket : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Newmarket : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oakville : 1160.129.06017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oakville :

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Oshawa : 1160.129.06001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oshawa :

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Ottawa : Ottawa Hospital-General Campus

Insulin Resistance Intervention After Stroke Trial

Ottawa : Ottawa Hospital-General Campus

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Peterborough : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Quebec : IUCPQ

Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial

Quebec : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Québec : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Québec : 1160.129.06006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Quebec City : Centre Hospitalier Affilie Universitaire de Quebec

Insulin Resistance Intervention After Stroke Trial

Quebec, QC :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Richmond : 1160.129.06034 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sainte-Foy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sainte-Foy : 1160.129.06022 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sarnia, ON :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Saskatoon : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saskatoon : 1160.129.06002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Scarborough : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sherbrooke : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St Johns, NF :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

St. John's : 1160.129.06007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ste-Foy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St-Jean-sur-Richel : 1160.129.06030 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St-Jean-sur-Richelieu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Surrey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Terrebonne : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thetford Mines : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thornhill, ON :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Thunder Bay : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thunder Bay : Intermountain Research Consultants

Insulin Resistance Intervention After Stroke Trial

Toronto : University Health Network

A Clinical Trial of IntensiVE Dialysis

Toronto : St Michael's Hospital

A Clinical Trial of IntensiVE Dialysis

Toronto : Sunnybrook Health Sciences Centre

Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A

Toronto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Toronto : CA012

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Toronto : CA002

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Toronto :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Toronto : 1160.129.06029 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06031 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toronto : St. Michael's Hospital

Insulin Resistance Intervention After Stroke Trial

Toronto : University Health Network - Toronto General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Toronto, ON :

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Vancouver : UBC

A Clinical Trial of IntensiVE Dialysis

Vancouver : St-Paul's Hospital

Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial

Victoria : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Victoria : CA005

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Victoria : 1160.129.06021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Victoria : Vancouver Island Health Research Centre

Insulin Resistance Intervention After Stroke Trial

Winnipeg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Winnipeg : Merz Investigational Site #001202

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Baotou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beijing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beijing : Weiwei Zhang

Chinese Assessment for Vinpocetine In Neurology

Changsha : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chongqing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dalian : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guang Zhou City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guangzhou : Zhujiang Hospital, Southern Medical University

Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke

Guangzhou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hangzhou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hong Kong : Queen Mary Hospital

A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial

Hong-Kong : Prince of Wales Hospital

Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)

Nanchang :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Nanjing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shanghai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shanghai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shatin : The Prince of Wales Hospital

A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial

Shenyang : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Suzhou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tianjin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tianjin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wuhan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Xi'an : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Xi'an :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Baranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Barranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Barranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bogotá : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bogotá : 1160.129.24006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bucaramanga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucaramanga : Universidad Autónoma de Bucaramanga

Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)

Cali : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cartagena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cartagena de Indias : 1160.129.24007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Cartegena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Florida Blanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Floridablanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Manizales : 1160.129.24008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Quindio : 1160.129.24005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Zagreb : Department of Neurology, University Hospital Sestre Milosrdnice

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Benesov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brno : Fakultní nemocnice u sv. Anny v Brne

Effect of F2695 on Functional Recovery After Ischemic Stroke

Brno : Merz Investigational Site #420029

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Brno :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Brno : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Broumov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hradec Kralové : Fakultní nemocnice Hradec Králové

Effect of F2695 on Functional Recovery After Ischemic Stroke

Jablonec nad Nisou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jihlava : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Kladno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Litomyšl : Litomyšlská Nemocnice, a.s.

Effect of F2695 on Functional Recovery After Ischemic Stroke

Louny : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Marianske lazne : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Most : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Olomouc : Merz Investigational Site #420028

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Ostrava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ostrava : Fakultní Nemocnice Ostrava

Effect of F2695 on Functional Recovery After Ischemic Stroke

Ostrava-Poruba : Merz Investigational Site #420024

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Ostrava-Vitkovice : Merz Investigational Site #420031

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Pardubice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plzen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plzen - Lochotin : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Prague 4 - Krc : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha : Merz Investigational Site #420030

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Praha 11 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 2 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 2 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 9 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rychnov nad Kneznou : Merz Investigational Site #420047

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Slany : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Uherske Hradiste : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Usti nad Labem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Usti nad Orlici : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vyskov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Znojmo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Aalborg : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Aarhus : DK001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Arhus : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Copenhagen : Rigshospitalet

GORE® HELEX® Septal Occluder / GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study

Copenhagen NV : DK004

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Hellerup :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Herning :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

København NV :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Odense C : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Viborg :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Valencia : 1160.136.03021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Parnu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saku : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tallin : 1160.136.38001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Tallinn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tallinn : EE002

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Tallinn : EE003

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Tallinn : EE004

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Tallinn : 1160.136.38002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Tartu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tartu : EE001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Viljandimaa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Võru : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Helsinki : FI001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Helsinki :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Jyväskylä :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Lappeenranta :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Oulu :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Pori :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tampere :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Turku : FI003

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Turku :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Vaasa :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Arras :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Aubervilliers : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Avignon : 1160.136.13060 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bagnols sur Ceze : 1160.136.13035 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bersée : 1160.136.13015 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Besancon : FR004

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Besancon : 1160.136.13039 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Beziers : 1160.136.13036 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Beziers : 1160.136.13040 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bordeaux : FR013

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Bordeaux : 1160.136.13004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bordeaux : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Bourg-en-Bresse : FR003

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Brest Cedex :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Brive La Gaillarde : 1160.136.13076 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Brive La Gaillarde : 1160.136.13087 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Broglie : 1160.136.13045 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bron : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

BRON Cedex :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Bruay la Buissière : 1160.136.13054 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Caen : FR015

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Cannes : 1160.136.13014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Chateauroux : 1160.136.13046 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Cherbourg : 1160.136.13025 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Cholet : 1160.136.13062 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Clermont Ferrand : 1160.136.13017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Clermont-Ferrand : Hôpital Gabriel Montpied

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Corbeil Essonnes : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Corbeil-Essonnes : 1160.136.13057 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Dijon : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Evecquemont : 1160.136.13063 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Garches : Merz Investigational Site #033018

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

La Teste de Buch : 1160.136.13005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lagny Sur Marne Cedex : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Le Chesnay : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Le Coudray : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Le Coudray : 1160.136.13058 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Levallois Perret : 1160.136.13010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Libourne : 1160.136.13044 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Libourne : 1160.136.13008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lille : FR014

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Lille Cedex :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Limoges : FR012

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Limoges : 1160.136.13078 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lyon : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Lyon : Hopital Neurologique de Lyon, Service d'urgences Neurovasculaires

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Many locations :

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Marseille : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Marseille :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Marseille : 1160.136.13080 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Marseille : 1160.136.13093 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Marseille : 1160.136.13075 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Marseille cedex 5 : 1160.136.13047 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Martigues : 1160.136.13100 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Massy : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Melun : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Mondelange : 1160.136.13019 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montargis : 1160.136.13056 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montauban : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Montauban : 1160.136.13053 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montauban : 1160.136.13013 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montfermeil : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Montfermeil : 1160.136.13001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montfermeil : 1160.136.13048 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montpellier : Hôpital Gui de Chauliac

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Montpellier : 1160.136.13072 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montreuil Cedex : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Neuilly Sur Seine : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Neuilly sur Seine : 1160.136.13064 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Nice : FR010

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Nice Cedex : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Nimes : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Nimes : 1160.136.13018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Nîmes : 1160.136.13085 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Nïmes : 1160.136.13049 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Orléans : 1160.136.13065 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Paris : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Paris : Hôpital Bichat-Claude Bernard

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Paris : FR009

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Paris : FR001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Paris :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Paris : BICHAT HOSPITAL Departement of Neurology

Treat Stroke to Target

Paris : BICHAT HOSPITAL Department of neurology and stroke center

Treat Stroke to Target

Paris cedex 13 :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Paris Cedex 13 : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Perpignan : FR007

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Pessac Cedex : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Poitiers : Centre Hospitalier Universitaire de Poitiers Hôpital de la Milétrie

Effect of F2695 on Functional Recovery After Ischemic Stroke

Quincy Sous Senart : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Rennes : Merz Investigational Site #033024

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Rennes Cedex : 1160.136.13066 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Rosiers d'Egletons : 1160.136.13042 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Rouen Cedex : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Saint-Yrieix-la-Perche : 1160.136.13026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Strasbourg : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Strasbourg : 1160.136.13030 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Strasbourg : 1160.136.13067 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Toulouse : Hôpital Rangueil

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Toulouse : Hôpital Purpan

Effect of F2695 on Functional Recovery After Ischemic Stroke

Toulouse : FR016

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Toulouse : 1160.136.13023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

TOULOUSE cedex :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tourcoing : 1160.136.13003 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Tours : 1160.136.13043 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Valence : 1160.136.13050 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Vandoeuvre-les-nancy :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Vendôme : 1160.136.13028 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Vihiers : 1160.136.13021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Wattrelos : 1160.136.13038 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Tblisi : Department of Neurology, S. Khechinashvili University clinic of Tbilisi state medical university

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Altenburg : Klinikum Altenburger Land

Insulin Resistance Intervention After Stroke Trial

Altenburg : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Anderbeck : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Augsburg :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Bad Friedrichshall : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Bad Krozingen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bad Nauheim : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Bad Neustadt : Neurologische Klinik

Insulin Resistance Intervention After Stroke Trial

Bad Neustadt/Saale : Neurologische Klinik GmbH

Effect of F2695 on Functional Recovery After Ischemic Stroke

Bad Oeynhausen :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Balve : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bayreuth : Department of Neurology, Klinikum Hohe Warte

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Beelitz-Heilstätten : Merz Investigational Site #049022

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Beelitz-Heilstätten : Kliniken Beelitz GmbH Neurologische Rehabilitationsklinik

SISTERS: Spasticity In Stroke Study - Randomized Study

Bennewitz :

Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]

Berlin :

Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]

Berlin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Berlin : Merz Investigational Site #049127

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Berlin : DE002

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Berlin :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Berlin : 1160.136.02036 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02039 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02020 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : Ihre-Radiologen.de

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Berlin : Charite University (Center for Stroke Research Berlin CSB & NeuroCure Clinical Research Center NCRC)

Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)

Berlin : Vivantes Auguste Viktoria Klinikum Neurologie

Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)

Berlin : Unfallkrankenhaus Berlin Neurologie

Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)

Berlin : Vivantes Neukölln Neurologie

Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)

Berlin : Charite Campus Benjamin Franklin, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Bochum : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bonn : Ambulantes Neurologisches Rehabilitationszentrum

SISTERS: Spasticity In Stroke Study - Randomized Study

Borna : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Braunschweig : Klinikum Braunschweig, Department of Cardiothoracic Surgery

Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit

Bremen : 1160.136.02042 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Burgau : Therapiezentrum Burgau

SISTERS: Spasticity In Stroke Study - Randomized Study

Celle : Department of Neurology, Allgemeines Krankenhaus Celle

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Chemnitz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chemnitz : Department of Neurology, Klinikum Chemnitz gGmbH

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Darmstadt : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Dessau-Roßlau : 1160.136.02017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Detmold : 1160.136.02041 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Dillingen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dinslaken : 1160.136.02014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Dortmund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dortmund : 1160.136.02033 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Dortmund : Klinikum Dortmund GmbH

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Dresden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dresden : DE001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Dresden :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Dresden : University Hospital-Dresden

Insulin Resistance Intervention After Stroke Trial

Dresden : Department of Neurology, Universitaetsklinikum Carl Gustav Carus

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Duesseldorf : University Duesseldorf/Heinrich-Heine University

Insulin Resistance Intervention After Stroke Trial

Duesseldorf : Heinrich-Heine-University Duesseldorf, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Duisburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Düsseldorf : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Düsseldorf : Merz Investigational Site #049071

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Ebersbach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Elsterwerda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Erlangen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Erlangen : Universitätsklinikum Erlangen

Effect of F2695 on Functional Recovery After Ischemic Stroke

Erlangen :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Erlangen : Erlangen University Clinic

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Erlangen : University of Erlangen

Insulin Resistance Intervention After Stroke Trial

Essen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Essen :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Essen : Essen University Clinic

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Essen : Alfried Krupp Hospital

Insulin Resistance Intervention After Stroke Trial

Esslingen : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Falkensee : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Frankfurt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Frankfurt : CardioVascular Center Frankfurt, Sankt Katharinen

Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.

Frankfurt :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Frankfurt : University Hospital Frankfurt

Insulin Resistance Intervention After Stroke Trial

Frankfurt : CardioVascular Center Frankfurt

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Frankfurt (Oder) : Klinikum Frankfurt (Oder) Neurologie

Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)

Freiburg : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Freiburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Freiburg : Freiburger Universitätsklinik

Effect of F2695 on Functional Recovery After Ischemic Stroke

Freiburg :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Freiburg : Freiburg University

Insulin Resistance Intervention After Stroke Trial

Freiburg : GSK Investigational Site Updated

POC in Patients With Ischaemic Stroke

Fulda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Giengen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Giessen : University of Giessen-Marburg Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Griefswald : Ernst-Moritz-Arndt-University Greifswald

Insulin Resistance Intervention After Stroke Trial

Haag : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Halle : Martin-Luther-Universitaet Halle-Wittenberg

Insulin Resistance Intervention After Stroke Trial

Halle/'Saale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hamburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hamburg : Merz Investigational Site #049079

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Hamburg :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hamburg : University Medical Center Hamburg-Eppendorf

Insulin Resistance Intervention After Stroke Trial

Hamburg : Hamburg University Cardiovascular Center

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Hamburg : Department of Neurology, Universitaetsklinikum Hamburg-Eppendorf

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Hannover : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Hannover : Hannover Medical School, Clinic for Cardiac, Thoracic, Transplantation and Vascular Surgery

Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit

Heidelberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heidelberg : Stroke Unit, Dept. of Neurology, University Hospital Heidelberg

Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling (HAIS-SE)

Heidelberg : Heidelberg University Clinic

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Heidelberg : University Heidelberg

Insulin Resistance Intervention After Stroke Trial

Heidenau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heilbronn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ingolstadt : 1160.136.02051 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Jena :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Jena : Friedrich Schiller-University Jena

Insulin Resistance Intervention After Stroke Trial

Jena : Department of Neurology, Universitaetsklinikum Jena

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Jerichow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kallstadt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kamp-Lintfort : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Karlsruhe :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Kassel : 1160.136.02022 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Kempen : 1160.136.02009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Kiel : Merz Investigational Site #049304

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Kirchzarten : 1160.136.02030 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Koblenz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Köln : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kuenzing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leipzig : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leipzig : Universitätsklinikum Leipzig

Effect of F2695 on Functional Recovery After Ischemic Stroke

Leipzig : DE003

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Leipzig :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Leipzig : Leipzig University Clinic

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Leipzig : GSK Investigational Site Updated

POC in Patients With Ischaemic Stroke

Leipzig : Herzzentrum and Park-Krankenhaus

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Leipzig : Department of Neurology, Universitaetsklinikum Leipzig

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Leipzig : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Leverkusen : 1160.136.02026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lübeck : DE022

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Ludenscheid : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Ludwigsburg : 1160.136.02008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Ludwigshafen : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Ludwigshafen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Luebben :

Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]

Lüneburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Magdeburg : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Mainz : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Mainz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mainz : 1160.136.02053 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Mainz : University Hospital Mainz

Insulin Resistance Intervention After Stroke Trial

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Markkleeberg : 1160.136.02012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Mayen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Meissen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Merseburg : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Mönchengladbach :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Muehldorf am Inn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Muehlhausen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Muenchen : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Muenster : University Hospital Muenster

Insulin Resistance Intervention After Stroke Trial

Mühldorf : 1160.136.02007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Mühlhausen / Thürigen : Dept. of Neurology, Ökumenisches Hainich Klinikum gGmbH

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Mühlheim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

München : Merz Investigational Site #049072

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

München : Merz Investigational Site #049148

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

München : 1160.136.02010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

München : Ludwig-Maximilians-University of Munich, Klinikum München-Großhadern, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Munich : Klinikum der Universitat Muenchen

Insulin Resistance Intervention After Stroke Trial

Munich : Site 01: Department of Neurology, TU Munich

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Munich : Städtisches Klinikum München GmbH Klinikum Neuperlach

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Münster : Universitätsklinikum Münster

Effect of F2695 on Functional Recovery After Ischemic Stroke

Münster : Site 03: Universitätsklinikum Münster

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Neuhofen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Neunkirchen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Northeim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Numbrecht : Rhein-Sieg-Klinik Dr. Becker Klinikgesellschaft

SISTERS: Spasticity In Stroke Study - Randomized Study

Nürnberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nürnberg :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Nürnberg : 1160.136.02004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Oelde : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oschatz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Paderborn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Potsdam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Potsdam : 1160.136.02031 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Rednitzhembach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Regensburg : Merz Investigational Site #049303

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Regensburg : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Reinfeld : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rostock : DE025

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Rotenburg a.d. Fulda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rüdersdorf : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Siegen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Teupitz : Asklepios Fachklinikum Teupitz

Effect of F2695 on Functional Recovery After Ischemic Stroke

Tübingen : Site 04: Universitätsklinikum Tübingen, Klinik für Allgemeine Neurologie

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Tuebingen : Department of Neurology, University Tuebingen

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Tutzing : Site 02: Benedictus Krankenhaus Tutzing GmbH u. Co. KG

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Ulm : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ulm : 1160.136.02005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Ulm : University of Ulm

Insulin Resistance Intervention After Stroke Trial

Ulm : University of Ulm, Department of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Villingen-Schwenningen : 1160.136.02037 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Vöhringen : 1160.136.02029 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Weinheim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wiesbaden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Witten : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wittenberg : 1160.136.02011 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Wolmirstedt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wuppertal : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Würzburg : Merz Investigational Site #049302

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Athens - GR : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Attica / Athens :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Chaidari : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chalikida : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heraklion : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heraklion :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Magoula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Patras : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thessaloniki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Voula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guatemala City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hong Kong : HK002

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Hong Kong : HK001

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Hong Kong : Queen Mary Hospital

Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia

Shatin : Prince of Wales Hospital

Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke

Balassagyarmat : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Budapest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Budapest : Magyar Honvédség Honvédkórház

Effect of F2695 on Functional Recovery After Ischemic Stroke

Budapest : Semmelweis Egyetem Neurológiai Klinika

Effect of F2695 on Functional Recovery After Ischemic Stroke

Budapest : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Debrecen :

BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

Debrecen :

BOTOX® Treatment in Pediatric Upper Limb Spasticity

Debrecen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Debrecen : Debreceni Egyetem Orvos- és Egészségtudományi Centrum

Effect of F2695 on Functional Recovery After Ischemic Stroke

Gyor : Petz Aladár Megyei Oktató Kórház

Effect of F2695 on Functional Recovery After Ischemic Stroke

Gyula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kaposvár : Kaposi Mór Megyei Oktató Kórhaz

Effect of F2695 on Functional Recovery After Ischemic Stroke

Kistarcsa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Komarom : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Miskolc : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Miskolc : BAZ Megyei és Egyetemi Oktató Kórház

Effect of F2695 on Functional Recovery After Ischemic Stroke

Mosonmagyarovar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagykanizsa : Kanizsai Dorottya Kórház

Effect of F2695 on Functional Recovery After Ischemic Stroke

Nyiregyháza : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nyíregyháza : Jósa András Oktató Kórház

Effect of F2695 on Functional Recovery After Ischemic Stroke

Pecs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Szeged : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Székesfehérvár : Fejér Megyei Szent György Kórház

Effect of F2695 on Functional Recovery After Ischemic Stroke

Szentes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Zalaegerszeg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kopavogur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Reykjavik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ahmedabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ahmedabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bangalore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bangalore : St. John's Medical College

Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)

Bengaluru : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bikaner : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chandigarh : IN004

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Coimbatore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ghaziabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guntur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guntur : IN009

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Hyderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyderabad : IN003

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Hyderabad : Care Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Jaipur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kochi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lucknow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ludhiana : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ludhiana : IN007

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

Madurai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Manipal : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mohali : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagpur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nashik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nellore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Delhi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Delhi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Delhi : Sir Ganga Ram Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Pune : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pune : Pfizer Investigational Site Updated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Rajasthan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Secunderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Surat : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tirupati : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vadodara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Varanasi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vijayawada : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vishakhapatnam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Yogyakarta : Stroke Unit, Department of Neurology, Faculty of Medicine, Gadjah Mada University, dr. Sardjito Hospital

Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

Galway :

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Beer Sheva : Soroka Medical Center

Insulin Resistance Intervention After Stroke Trial

Haifa : Rambam Medical Center

Electroencephalograph for Detection of Acute Ischemic Stroke

Haifa : Bnai-Zion Medical Center

Insulin Resistance Intervention After Stroke Trial

Haifa : B'nai Zion Medical Center

Insulin Resistance Intervention After Stroke Trial

Haifa : Rambam Medical Center

Insulin Resistance Intervention After Stroke Trial

Holon : Wolfson Medical Center

Insulin Resistance Intervention After Stroke Trial

Jerusalem : Hadassah Medical Organization

Evaluation of the Genu Neurexa Orthosis in Post Stroke Patients

Many Locations : Updated

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Petach Tikva : Rabin Medical Center-Golda Campus

Insulin Resistance Intervention After Stroke Trial

Ramat Gan : Sheba Medical Center

Insulin Resistance Intervention After Stroke Trial

Tel Aviv : Tel Aviv Medical Center

Insulin Resistance Intervention After Stroke Trial

Acquaviva delle Fonti :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Ancona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ancona :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Aosta :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Arezzo : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Ascoli Piceno : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Bergamo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brescia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Casorate Primo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Catania :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Catanzaro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chieti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cortona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Costa Masnaga : Centro di Riabilitazione "Villa Beretta"

SISTERS: Spasticity In Stroke Study - Randomized Study

Cotignola : Gruppo Villa Maria, Villa Maria Cecilia Hospital

Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.

Cotignola : Villa Maria Cecilia Hospital

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Fermo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ferrara : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Firenze : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Foggia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Foligno : Azienda Sanitaria Ospedaliera "San Giovanni Battista"

Effect of F2695 on Functional Recovery After Ischemic Stroke

Forli : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Genova : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Grosseto : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Imperia : IT004

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Lagosanto :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Laquila : University of Laquila

Insulin Resistance Intervention After Stroke Trial

Massa : Research Site

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Massa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Massa :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Mercogliano : Casa di Cura Privata "Montevergine" S.p.A.

Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.

Messina : Merz Investigational Site #039006

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Mestre :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Mestre :

Gadobutrol Enhanced MRA of the Supra-aortic Vessels